natgillin/translations-raw huggingface dataset:
Patients should be advised to have their rescue inhaler available at all times, either BiResp Spiromax (for asthma patients using BiResp Spiromax as maintenance and reliever therapy) or a separate rapid-acting bronchodilator (for asthma patients using BiResp Spiromax as maintenance therapy only).
Bolnikom svetujte, naj imajo inhalator z olajševalcem vedno pri roki, bodisi BiResp Spiromax (za bolnike z astmo, ki uporabljajo zdravilo BiResp Spiromax za vzdrževalno in olajševalno zdravljenje), ali pa samostojni hitrodelujoči bronhodilatator (za bolnike, ki uporabljajo zdravilo BiResp Spiromax le za vzdrževalno zdravljenje).
Patients should be advised to have their rescue inhaler available at all times, either BiResp Spiromax (for asthma patients using BiResp Spiromax as maintenance and reliever therapy) or a separate rapid-acting bronchodilator (for asthma patients using BiResp Spiromax as maintenance therapy only).
Bolnikom svetujte, naj imajo inhalator z olajševalemc vedno pri roki, bodisi BiResp Spiromax (za bolnike z astmo, ki uporabljajo zdravilo BiResp Spiromax za vzdrževalno in olajševalno zdravljenje), ali pa samostojni hitrodelujoči bronhodilatator (za bolnike, ki uporabljajo zdravilo BiResp Spiromax le za vzdrževalno zdravljenje).
Patients should be advised to have their rescue inhaler available at all times, either DuoResp Spiromax (for asthma patients using DuoResp Spiromax as maintenance and reliever therapy) or a separate rapid-acting bronchodilator (for asthma patients using DuoResp Spiromax as maintenance therapy only).
Bolnikom svetujte, naj imajo inhalator z olajševalcem vedno pri roki, bodisi DuoResp Spiromax (za bolnike z astmo, ki uporabljajo zdravilo DuoResp Spiromax za vzdrževalno in olajševalno zdravljenje), ali pa samostojni hitrodelujoči bronhodilatator (za bolnike, ki uporabljajo zdravilo DuoResp Spiromax le za vzdrževalno zdravljenje).
Patients should be advised to have their rescue inhaler available at all times, either DuoResp Spiromax (for asthma patients using DuoResp Spiromax as maintenance and reliever therapy) or a separate rapid-acting bronchodilator (for asthma patients using DuoResp Spiromax as maintenance therapy only).
Bolnikom svetujte, naj imajo inhalator z olajševalemc vedno pri roki, bodisi DuoResp Spiromax (za bolnike z astmo, ki uporabljajo zdravilo DuoResp Spiromax za vzdrževalno in olajševalno zdravljenje), ali pa samostojni hitrodelujoči bronhodilatator (za bolnike, ki uporabljajo zdravilo DuoResp Spiromax le za vzdrževalno zdravljenje).
Patients should be advised to have their separate rapid-acting bronchodilator reliever inhaler available for rescue use at all times.
Bolnikom je treba svetovati, naj imajo svoj ločeni hitrodelujoči bronhodilatator oz. inhalator z olajševalcem vedno na razpolago za hitro obvladanje astme.
Patients should be advised to keep capsules out of the sight and reach of children, preferably in a locked cupboard.
Bolnikom je treba svetovati, naj zdravilo shranjujejo nedosegljivo otrokom, najbolje v zaklenjeni omarici.
Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole.
Bolnicam je treba naročiti, da morajo obvestiti svojega zdravnika, če med zdravljenjem z aripiprazolom zanosijo ali nameravajo zanositi.
Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with olanzapine.
Bolnicam je treba svetovati, da naj obvestijo svojega zdravnika, če zanosijo ali nameravajo zanositi med zdravljenjem z olanzapinom.
Patients should be advised to promptly report febrile episodes.
Bolnikom svetujte, naj nemudoma poročajo o febrilnih epizodah.
Patients should be advised to promptly report severe, persistent, and/or worsening symptoms.
Bolnikom je treba svetovati, naj hude ali perzistentne simptome oziroma njihovo poslabšanje, čim prej sporočijo.
Patients should be advised to report excessive thirst or any increase in the volume or frequency of urination.
Bolnike je treba opozoriti, naj poročajo o čezmerni žeji ali zvečanju količine ali pogostnosti uriniranja.
Patients should be advised to report immediately to their physician any symptoms indicative of infection such as fever, sore throat and flu-like symptoms.
Bolnikom je potrebno svetovati, naj nemudoma obvestijo zdravnika o vseh simptomih, ki kažejo na okužbo, kot so zvišana telesna temperatura, vneto grlo in simptomi, podobni gripi.
Patients should be advised to seek immediate medical advice if they experience any delayed adverse event (see section 4.8).
Bolnikom naročite, naj nemudoma poiščejo zdravniško pomoč, če opazijo katerega od poznih neželenih učinkov (glejte poglavje 4.8).
Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.
Bolnikom je treba pojasniti, da morajo v primeru bolečnosti in bolečin v sklepih, okorelosti sklepov ali težav pri gibanju poiskati zdravniško pomoč.
Patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines, in particular when Victoza is used in combination with a sulfonylurea or a basal insulin.
Bolnikom je treba svetovati, naj upoštevajo previdnostne ukrepe in se tako izognejo hipoglikemiji med vožnjo in upravljanjem strojev, predvsem kadar uporabljajo zdravilo Victoza skupaj s sulfonilsečnino ali z bazalnim insulinom.
Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation on Aerivio Spiromax.
Bolnikom je treba naročiti, naj z zdravljenjem nadaljujejo, vendar naj se posvetujejo z zdravnikom, če simptomi astme niso pod nadzorom ali če se po uvedbi zdravila Airexar Spiromax poslabšajo.
Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation with Budesonide/Formoterol Teva Pharma B.V.
Če po uvedbi zdravila Budezonid/formoterol Teva Pharma B.V. simptomi astme niso nadzorovani ali se poslabšajo, naj bolniki nadaljujejo z zdravljenjem in poiščejo zdravniško pomoč.
Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation with Budesonide/Formoterol Teva.
Če po uvedbi zdravila Budezonid/formoterol Teva simptomi astme niso nadzorovani ali se poslabšajo, naj bolniki nadaljujejo z zdravljenjem in poiščejo zdravniško pomoč.
Patients should be assessed for the risk of developing serious bacterial, mycobacterial, fungal and viral infections.
Pri bolnikih je treba oceniti tveganje za razvoj resnih bakterijskih, mikobakterijskih, glivičnih in virusnih okužb.
Patients should be aware of how they might be affected by ambrisentan before driving or using machines.
Bolniki morajo biti seznanjeni, kako bi nanje lahko vplival ambrisentan, preden vozijo ali upravljajo s stroji.
Patients should be aware of how they react to this medicine, before driving or operating machines.
Bolniki morajo pred vožnjo ali upravljanjem s stroji vedeti, kako se odzivajo na to zdravilo.
Patients should be aware of potential risk factors (skin phototype and hepatic impairment).
Bolniki morajo biti seznanjeni z možnimi nevarnostmi (fototip kože in okvare jeter).
Patients should be aware of the long half-life of porfimer and that the compound gets activated by light.
Bolnike je potrebno seznaniti z daljšim razpolovnim časom porfirinov in o načinu aktiviranja porfirinov z osvetlitvijo.
Patients should be aware of the risk of pregnancy (see section 4.6).
Bolnice se morajo zavedati tveganja nosečnosti (glejte poglavje 4.6).
Patients should be carefully assessed for their ability to tolerate lenalidomide in combination, with consideration to age, ISS stage III, ECOG PS≤2 or CLcr<60 mL/min (see section 4.2 and 4.8).
Bolnike morate skrbno oceniti glede njihove sposobnosti prenašanja lenalidomida v kombinaciji, z upoštevanjem starosti, stadija III ISS, ECOG PS≤2 ali CLcr<60 ml/min (glejte poglavji 4.2 in 4.8).
Patients should be carefully monitored during treatment.
Bolnike je treba med zdravljenjem skrbno nadzirati.
Patients should be carefully monitored following primary PCI for signs and symptoms consistent with myocardial ischaemia.
Bolniki po osnovni PCI morajo biti pod strogim nadzorom glede kakršnih koli znakov in simptomov, ki bi kazali na srčno ishemijo.
Patients should be carefully monitored for adverse events if one of these agents is used together with sonidegib.
Pri sočasni uporabi sonidegiba in katerega od navedenih zdravil je treba bolnika skrbno spremljati glede pojavljanja neželenih dogodkov.
Patients should be carefully monitored for adverse reactions when oral topotecan is administered with a drug known to inhibit ABCB1 or ABCG2 (see section 5.2).
Če peroralni topotekan uporabljate s kakšnim zdravilom, ki zavira ABCB1 ali ABCG2, morate bolnike natančno spremljati glede neželenih reakcij (glejte poglavje 5.2).
Patients should be carefully monitored for liver damage and for worsening of renal function.
Bolnike je treba pozorno spremljati zaradi možnih poškodb jeter in poslabšanja v delovanju ledvic.
Patients should be carefully monitored for safety.
Bolnike je treba skrbno spremljati glede varnosti.
Patients should be carefully monitored with regard to safety and efficacy during Jakavi treatment.
Bolnike je treba v času zdravljenja z zdravilom Jakavi skrbno spremljati glede varnosti in učinkovitosti.
Patients should be cautioned about operating hazardous machines, including motor vehicles, until they are reasonably certain that AZILECT does not affect them adversely.
Bolnike je potrebno opozoriti, naj ne upravljajo nevarnih strojev, vključno z motornimi vozili, dokler niso ustrezno prepričani, da zdravilo AZILECT na njih ne vpliva škodljivo.
Patients should be cautioned about operating hazardous machines, including motor vehicles, until they are reasonably certain that Rasagiline ratiopharm does not affect them adversely.
Bolnike je potrebno opozoriti, naj ne upravljajo nevarnih strojev, vključno z motornimi vozili, dokler niso ustrezno prepričani, da zdravilo Razagilin ratiopharm na njih ne vpliva škodljivo.
Patients should be closely monitored (e.g. twice weekly) for cytopenias and dose titrated based on safety and efficacy (see section 4.2).
Bolnike je treba skrbno spremljati (na primer dvakrat tedensko) glede citopenije in odmerke titrirati glede na varnost in učinkovitost (glejte poglavje 4.2).
Patients should be closely monitored after stopping treatment.
Po prenehanju zdravljenja je potrebno bolnike skrbno nadzorovati.
Patients should be closely monitored and Simponi must be discontinued in patients who develop new or worsening symptoms of heart failure (see section 4.3).
Bolnike skrbno spremljajte in pri tistih, ki se jim na novo pojavijo znaki srčnega popuščanja oziroma se ti poslabšajo, ukinite zdravilo Simponi (glejte poglavje 4.3).
Patients should be closely monitored and the dose titrated based on safety and efficacy (see section 4.2).
Bolnike je treba skrbno spremljati in odmerke titrirati glede na varnost in učinkovitost (glejte poglavje 4.2).
Patients should be closely monitored during administration of ofatumumab for the onset of infusion reactions, including cytokine release syndrome, particularly during the first infusion.
Bolnike je treba med dajanjem ofatumumaba skrbno nadzirati glede nastopa infuzijskih reakcij,
Patients should be closely monitored during administration of ofatumumab for the onset of infusion reactions, including cytokine release syndrome, particularly during the first infusion.
Bolnike je treba med dajanjem ofatumumaba skrbno nadzirati glede nastopa infuzijskih reakcij, vključno s sindromom sproščanja citokinov, posebno med prvo infuzijo.
Patients should be closely monitored for dose related adverse reactions (see section 4.4).
Pri bolnikih je treba skrbno spremljati morebiten pojav neželenih učinkov, povezanih z odmerkom (glejte poglavje 4.4).
Patients should be closely monitored for signs and symptoms of excessive exposure to themedicinal products and reduction of the dose of these medicinal products should be considered.
Bolnike je treba skrbno spremljati glede znakov in simptomov prekomerne izpostavljenosti zdravilom in v poštev pride zmanjšanje odmerka teh zdravil.
Patients should be closely monitored for signs and symptoms of viral reactivation, including active HBV infection throughout therapy.
Bolnike je treba ves čas zdravljenja skrbno spremljati glede znakov in simptomov virusne reaktivacije, vključno z aktivno okužbo s HBV.
Patients should be closely monitored for signs of toxicity or lack of efficacy if they have been given oritavancin while on a potentially affected compound (e.g. patients should be monitored for bleeding if concomitantly receiving oritavancin and warfarin) (see section 4.4).
Pri bolnikih je treba natančno spremljati znake toksičnosti ali pomanjkanja učinkovitosti, če dobivajo oritavancin sočasno z drugo zdravilno učinkovino, ki jo to zadeva (pri bolnikih je treba npr. spremljati znake krvavitve, če sočasno prejemajo oritavancin in varfarin) (glejte poglavje 4.4).
Patients should be closely monitored for tenofovir disoproxil fumarate-associated adverse reactions, including renal disorders.
Bolnike je treba skrbno nadzirati glede pojava neželenih učinkov dizoproksiltenofovirat fumarata, vključno z motnjami delovanja ledvic.
Patients should be closely monitored for tenofovir- associated adverse reactions, including renal disorders.
Bolnike je treba skrbno nadzirati glede pojava neželenih učinkov tenofovirja, vključno z motnjami delovanja ledvic.
Patients should be closely monitored for thrombocytopenia, especially during the first cycle; regular laboratory tests should be performed until the event resolves, and dose delays should be considered in case of severe or life-threatening thrombocytopenia.
Bolnike je treba natančno spremljati glede trombocitopenije, zlasti v prvem ciklusu; izvajati je treba redne laboratorijske preiskave krvne slike, dokler dogodek ne mine, pri hudi ali življenje ogrožajoči trombocitopeniji pa je treba razmisliti o preložitvi odmerka na kasnejši čas.
Patients should be closely monitored throughout this period.
Bolnike je treba ves čas natančno nadzirati.
Patients should be closely monitored when given Bortezomib Hospira in combination with potent CYP3A4-inhibitors.
Bolnike, ki prejemajo zdravilo Bortezomib Hospira v kombinaciji z močnimi inhibitorji encima CYP3A4, je treba skrbno spremljati.
Patients should be closely monitored when given bortezomib in combination with potent CYP3A4 inhibitors.
Bolnike, ki prejemajo bortezomib v kombinaciji z močnimi inhibitorji encima CYP3A4, je treba skrbno spremljati.
Patients should be counseled about the risks of gastrointestinal injury and bleeding while taking clopidogrel plus ASA with alcohol, especially if alcohol consumption is chronic or heavy. (See section 4.4.)
Bolnike je treba opozoriti o povečani nevarnosti gastrointestinalnih poškodb in krvavitev pri sočasnem zaužitju klopidogrela in ASA z alkoholom, še posebej, če gre za veliko ali kronično rabo alkohola (glejte poglavje 4.4).
Patients should be counseled about the risks of gastrointestinal injury and bleeding while taking clopidogrel plus ASA with alcohol, especially if alcohol consumption is chronic or heavy. (See section 4.5.)
Bolnike je treba opozoriti o povečani nevarnosti gastrointestinalnih poškodb in krvavitev pri sočasnem zaužitju klopidogrela in ASA z alkoholom, še posebej, če gre za veliko ali kronično rabo alkohola (glejte poglavje 4.5).
Patients should be counselled to seek medical advice should any of these symptoms occur.
Bolnikom morate svetovati, da ob pojavu teh simptomov poiščejo zdravniško pomoč.
Patients should be evaluated after two weeks and treatment should be stopped for those who have not shown an improvement.
Po dveh tednih zdravljenja je treba bolnike oceniti in pri tistih, pri katerih ni izboljšanja, zdravljenje prekiniti.
Patients should be evaluated for history of hypersensitivity to thienopyridines (such as clopidogrel, ticlopidine, prasugrel) since cross-reactivity among thienopyridines has been reported (see section 4.8).
Bolnike je treba oceniti glede na anamnezo preobčutljivosti na tienopiridine (naprimer na klopidogrel, tiklopidin in prasugrel), ker so poročali o navzkrižnih alergijah med tienopiridini (glejte poglavje 4.8).
Patients should be evaluated for history of hypersensitivity to thienopyridines (such as clopidogrel, ticlopidine, prasugrel) since cross-reactivity among thienopyridines has been reported (see section 4.8).
Bolnike je treba oceniti glede na anamnezo preobčutljivosti natienopiridine (na primer na klopidogrel, tiklopidin in prasugrel), ker so poročali o navzkrižnih alergijah med tienopiridini (glejte poglavje 4.8).
Patients should be evaluated for signs and symptoms of underlying cardiopulmonary disease prior to initiating dasatinib therapy.
Pred uvedbo zdravljenja z dasatinibom je pri bolniku treba ovrednotiti znake in simptome že prisotne kardiopulmonalne bolezni.
Patients should be examined at regular intervals for the presence of oral ulceration or any oral discomfort that may be indicative of secondary oral cancer.
Bolnike je treba redno pregledovati na prisotnost razjed v ustni votlini ali kakršnega koli neugodja v ustih, ki bi lahko kazalo na sekundarno neoplazmo v ustih.
Patients should be given intravenous diphenhydramine 25 mg to 50 mg (or similar antihistamine) approximately 30 minutes before the start of each dose of temsirolimus (see section 4.4).
Približno 30 minut pred začetkom vsakega odmerka temsirolimusa naj bolniki intravensko prejmejo difenhidramin (ali podoben antihistaminik) v odmerku od 25 mg do 50 mg (glejte poglavje 4.4).
Patients should be given the package leaflet and the Patient Alert Card.
Bolniki morajo prejeti navodilo za uporabo in opozorilno kartico.
Patients should be given the Ranexa package leaflet and the Patient Alert Card and instructed to present their Patient Alert Card and medication list to their health care professional at each visit.
Bolnikom je treba dati navodilo za uporabo zdravila Ranexa in kartico z opozorili za bolnika ter jim naročiti, naj pri vsakem obisku zdravniku pokažejo kartico z opozorili za bolnika in seznam zdravil.
Patients should be given the special alert card.
Bolniki, ki se zdravijo z zdravilom Cimzia, morajo prejeti posebno opozorilno kartico.
Patients should be individually titrated to the dose that provides adequate analgesia with tolerable adverse drug reactions.
Bolnike je treba posamično titrirati do odmerka, ki zagotavlja zadostno protibolečinsko delovanje ob znosnih neželenih učinkih zdravila.
Patients should be informed about the expected adverse reactions of headache, nausea, vomiting and fever, and about the early signs and symptoms of neurotoxicity.
Bolnike morate obvestiti o pričakovanih neželenih reakcijah glavobola, utrujenosti, bruhanja in povišane telesne temperature ter o zgodnjih znakih in simptomih nevrotoksičnosti.
Patients should be informed about the potential risk of fibrosing colonopathy;
bolnike je treba seznaniti z možnim tveganjem za fibrozirajočo kolonopatijo;
Patients should be informed of symptoms of these potential adverse reactions and instructed to inform their physician if they develop signs such as eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small particles in their vision, or increased sensitivity to light.
Bolnike je treba poučiti o simptomih navedenih možnih neželenih učinkov in jim naročiti, da obvestijo svojega zdravnika v primeru bolečin v očesu ali povečane občutljivosti očesa, vedno bolj izražene rdečine očesa, zamegljenega ali poslabšanega vida, povečanja števila drobnih delcev v vidnem polju ali povečane občutljivosti na svetlobo.
Patients should be informed of the characteristic symptom of pancreatitis that, if left untreated, could become fatal: persistent abdominal pain that could be severe, which may radiate to the back.
Bolnike moramo poučiti o značilnem simptomu pankreatitisa, ki je lahko smrten, če ga ne zdravimo: vztrajne bolečine v trebuhu, ki so lahko hude in lahko sevajo v hrbet.
Patients should be informed of the early signs of anaphylaxis/hypersensitivity (hives, pruritus, generalized urticaria, tightness of the chest, wheezing, and hypotension).
Bolnike morate poučiti o zgodnjih znakih anafilaksije/preobčutljivosti (koprivnica, srbenje, generalizirana urtikarija, tiščanje v prsih, sopenje in hipotenzija).
Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of chest, wheezing, hypotension and anaphylaxis.
Bolnike poučite o prvih znakih preobčutljivostnih reakcij, kot so izpuščaji, generalizirana koprivnica, tiščanje v prsnem košu, sopenje, hipotenzija in anafilaksija.
Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis.
Bolnike je treba poučiti o zgodnjih znakih preobčutljivostnih reakcij, ki vključujejo koprivnico, splošno urtikarijo, stiskanje v prsih, hropenje, hipotenzijo in anafilakso.
Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis.
Bolnike je treba seznaniti z zgodnjimi znaki preobčutljivostnih reakcij, vključno s koprivnico, generalizirano urtikarijo, tiščanjem v prsih, piskajočim dihanjem, hipotenzijo in anafilaksijo.
Patients should be informed of the early signs of hypersensitivity reactions including urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis.
Bolnike je treba poučiti o zgodnjih znakih preobčutljivostnih reakcij, vključujoč koprivnico, tiščoč občutek v prsnem košu, piskajoče in sopihajoče dihanje, hipotenzijo, in o anafilaksiji.
Patients should be informed of the early signs of hypersensitivity reactions, which may include angioedema, burning and stinging at the injection site, chills, flushing, rash, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting and wheezing.
Bolnike poučite o zgodnjih znakih preobčutljivostnih reakcij, med katere lahko sodijo angioedem, občutek pečenja ali zbadanja na mestu injiciranja zdravila, mrzlica, pordelost, izpuščaj, generalizirana urtikarija, glavobol, koprivnica, hipotenzija, letargija, slabost, nemir, tahikardija, stiskanje v prsih, mravljinci, bruhanje in piskanje v pljučih.
Patients should be informed of the early signs of hypersensitivity reactions, which may include angioedema, burning and stinging at the injection site, chills, flushing, rash, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, and wheezing.
Bolnike poučite o zgodnjih znakih preobčutljivostnih reakcij, med katere lahko sodijo angioedem, občutek pečenja ali zbadanja na mestu injiciranja zdravila, mrzlica, pordelost, izpuščaj, generalizirana urtikarija, glavobol, koprivnica, hipotenzija, letargija, slabost, nemir, tahikardija, stiskanje v prsih, mravljinci, bruhanje in piskanje v pljučih.
Patients should be informed of the first signs of gastrointestinal perforations and advised to consult rapidly the treating physician in case of occurrence.
Bolnike je treba poučiti o prvih znakih perforacije v prebavilih in jim svetovati, naj se ob njihovem pojavu nemudoma posvetujejo z zdravnikom.
Patients should be informed that (mostly visual) hallucinations can occur.
Bolnike moramo opozoriti, da lahko pride do halucinacij (večinoma vidnih).
Patients should be informed that consumption of grapefruit or its juice should be avoided.
Bolnikom je treba naročiti, naj se izogibajo uživanju grenivk in pitju soka grenivk.
Patients should be informed that dizziness has been reported during treatment with Descovy.
Bolnike je potrebno opozoriti, da se lahko v času zdravljenja z zdravilom Descovy pojavi omotičnost.
Patients should be informed that dizziness has been reported during treatment with Genvoya.
Bolnike je potrebno opozoriti, da se lahko v času zdravljenja z zdravilom Genvoya pojavi omotičnost.